Blueprint Medicines to Present Preclinical Data on BLU-554 and on Novel Drug Target at International Liver Cancer Association 9th Annual Conference
BLU-554 as a Molecularly Targeted Therapy for HCC
BLU-554 is an exquisitely selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) and represents a promising new approach for molecularly targeted therapy in HCC. Liver cancer is the second leading cause of cancer-related deaths worldwide, with HCC accounting for most liver cancers. The oral presentation at ILCA details the prevalence of aberrant FGFR4 signaling, triggered by overexpression of the FGF19 ligand, in HCC, as well as preclinical data demonstrating BLU-554's anti-tumor activity in preclinical models of HCC dependent on aberrant FGFR4 signaling. BLU-554 is currently being studied in a Phase 1 trial in HCC and cholangiocarcinoma, cancer of the bile duct in which aberrant FGFR4 signaling may play a key role.
- Date & Time:
Sunday, Sept. 6 from10:45 a.m.-12:15 p.m. (CEST) - Presentation Title: FGF19 Aberrations and Selective Targeting with FGFR4 Inhibitors for Hepatocellular Carcinoma
- Session Title: General Session 5: From Drivers to Clinical Trials
- Presenter:
Ben Wolf , M.D., Ph.D., Vice President of Clinical Development,Blueprint Medicines - Abstract Number: 0-030
- Location: Scene AB Ground Level
Novel Drug Target for FL-HCC
Using a proprietary computational approach to identify kinase fusions as drivers of cancer,
- Date & Time:
Friday, Sept. 4 from11:15 a.m.-12:45 p.m. (CEST) - Presentation Title: Interrogation of DNAJB1-PRKACA Kinase Fusion as a Therapeutic Target in Fibromellar Hepatocelllular Carcinoma
- Presenter:
Stefanie Schalm , Ph.D., Senior Scientist,Blueprint Medicines - Session Title: General Session 1: Molecular Pathogenesis of Liver Cancer I
- Abstract Number: 0-006
- Location: Scene AB Ground Level
About
Forward-Looking Statements
Various statements in this release concerning
Logo - http://photos.prnewswire.com/prnh/20150605/221118LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-preclinical-data-on-blu-554-and-on-novel-drug-target-at-international-liver-cancer-association-9th-annual-conference-300135445.html
SOURCE
Investor Relations: Hannah Deresiewicz, Stern Investor Relations, Inc., 212-362-1200, hannahd@sternir.com; Media Relations: Naomi Aoki, Ten Bridge Communications, Inc., 617-283-4298, naomi@tenbridgecommunications.com